DN24-02
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DN24-02, covering 2017-05-25 to 2017-05-25. Get the full timeline:
Most recent: Clinical Trial Update: DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma [Phase 2]